Symbols / SLXN Stock $0.78 -14.90% Silexion Therapeutics Corp

Healthcare • Biotechnology • Israel • NCM
SLXN (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Ilan Hadar M.B.A.
Exch · Country NCM · Israel
Market Cap 3.19M
Enterprise Value -1.35M
Income -11.91M
Sales —
FCF (ttm) -6.51M
Book/sh 0.83
Cash/sh 1.80
Employees 13
Insider 10d —
IPO Apr 07, 2021
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E 0.00
Forward P/E -1.22
PEG —
P/S —
P/B 0.94
P/C —
EV/EBITDA 0.12
EV/Sales —
Quick Ratio 2.17
Current Ratio 2.41
Debt/Eq 78.22
LT Debt/Eq —
EPS (ttm) -8.96
EPS next Y -0.64
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2025-11-12
Earnings (prior) 2025-11-12
ROA -144.28%
ROE —
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 4.07M
Shs Float 3.30M
Insider Own 8.28%
Instit Own 4.23%
Short Float 1.36%
Short Ratio 0.61
Short Interest 46.47K
52W High 22.36
vs 52W High -96.50%
52W Low 0.74
vs 52W Low 5.53%
Beta 0.06
Impl. Vol. —
Rel Volume 3.22
Avg Volume 49.29K
Volume 158.55K
Target (mean) $6.00
Tgt Median $6.00
Tgt Low $6.00
Tgt High $6.00
# Analysts 2
Recom None
Prev Close $0.92
Price $0.78
Change -14.90%
About

Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. Silexion Therapeutics Corp has collaboration with Evonik Corporation for the development of an advanced siRNA formulation to enhance cancer treatment. The company was founded in 2008 and is headquartered in Jerusalem, Israel.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$6.00
Mean price target
2. Current target
$0.78
Latest analyst target
3. DCF / Fair value
$-28.75
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.78
Low
$6.00
High
$6.00
Mean
$6.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-12-15 init Litchfield Hills — → Buy $6
2025-03-20 main Maxim Group Buy → Buy $5
2024-11-01 init Maxim Group — → Buy $1
News
RSS: Latest SLXN news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-26 SHIRVAN MITCHELL PHD Officer — 22,818 $1.36 $31,032
2026-02-20 SHIRVAN MITCHELL PHD Officer — 49,726 $0.00 $0
2026-02-20 HADAR ILAN Chief Executive Officer — 64,350 $0.00 $0
2026-02-20 ALON RUTH Director — 9,091 $0.00 $0
2026-02-20 HORENSHTEIN HADAR MIRIT Chief Financial Officer — 49,726 $0.00 $0
2026-02-20 LUSHI AVNER Director — 9,091 $0.00 $0
2026-02-20 ABRAMOV DROR YOSEF Director — 9,091 $0.00 $0
2026-02-20 NOY SHLOMO Director — 9,091 $0.00 $0
2026-02-20 PELED AMNON PH.D. Director — 7,576 $0.00 $0
2025-09-15 LEVIN ILAN Director and Beneficial Owner of more than 10% of a Class of Security — 450,000 $4.00 $1,800,000
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
11.63
-7.47%
12.57
+168.55%
4.68
+21.27%
3.86
Research And Development
7.14
+22.79%
5.82
+56.82%
3.71
+14.94%
3.23
Selling General And Administration
4.48
-33.47%
6.73
+625.32%
0.93
+60.83%
0.58
General And Administrative Expense
4.48
-33.47%
6.73
+625.32%
0.93
+60.83%
0.58
Salaries And Wages
1.66
-63.83%
4.59
+1189.89%
0.36
+62.56%
0.22
Other Gand A
2.64
+28.78%
2.05
+321.81%
0.49
+69.34%
0.29
Total Expenses
11.63
-7.47%
12.57
+168.55%
4.68
+21.27%
3.86
Operating Income
-11.63
+7.47%
-12.57
-168.55%
-4.68
-21.27%
-3.86
Total Operating Income As Reported
11.63
-7.47%
12.57
+368.55%
-4.68
-21.27%
-3.86
EBITDA
-11.88
+27.89%
-16.48
-227.90%
-5.03
-32.13%
-3.80
Normalized EBITDA
-11.76
+27.57%
-16.23
-254.99%
-4.57
-45.00%
-3.15
Reconciled Depreciation
0.01
-44.00%
0.03
-44.44%
0.04
-21.05%
0.06
EBIT
-11.90
+27.91%
-16.50
-225.48%
-5.07
-31.35%
-3.86
Total Unusual Items
-0.13
+48.58%
-0.25
+45.47%
-0.45
+30.31%
-0.65
Total Unusual Items Excluding Goodwill
-0.13
+48.58%
-0.25
+45.47%
-0.45
+30.31%
-0.65
Net Income
-11.91
+27.56%
-16.44
-232.72%
-4.94
-53.72%
-3.21
Pretax Income
-11.91
+27.86%
-16.51
-225.24%
-5.08
-46.54%
-3.46
Net Non Operating Interest Income Expense
0.13
+102.66%
-4.84
-3461.81%
0.14
+396.55%
0.03
Interest Expense Non Operating
0.01
+85.71%
0.01
+16.67%
0.01
—
Net Interest Income
0.13
+102.66%
-4.84
-3461.81%
0.14
+396.55%
0.03
Interest Expense
0.01
+85.71%
0.01
+16.67%
0.01
—
Interest Income Non Operating
0.14
+14100.00%
0.00
-99.35%
0.15
+34.21%
0.11
Interest Income
0.14
+14100.00%
0.00
-99.35%
0.15
+34.21%
0.11
Other Income Expense
-0.41
-144.96%
0.90
+267.53%
-0.54
-246.87%
0.37
Other Non Operating Income Expenses
-0.28
-124.26%
1.15
+1437.21%
-0.09
-108.46%
1.02
Gain On Sale Of Security
-0.13
+48.58%
-0.25
+45.47%
-0.45
+30.31%
-0.65
Tax Provision
0.00
-70.00%
0.01
-68.75%
0.03
+33.33%
0.02
Tax Rate For Calcs
0.00
+0.00%
0.00
+0.00%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
-0.03
+48.58%
-0.06
+45.47%
-0.10
+30.31%
-0.15
Net Income Including Noncontrolling Interests
-11.91
+27.89%
-16.52
-223.39%
-5.11
-46.44%
-3.49
Net Income From Continuing Operation Net Minority Interest
-11.91
+27.56%
-16.44
-232.72%
-4.94
-53.72%
-3.21
Net Income From Continuing And Discontinued Operation
-11.91
+27.56%
-16.44
-232.72%
-4.94
-53.72%
-3.21
Net Income Continuous Operations
-11.91
+27.89%
-16.52
-223.39%
-5.11
-46.44%
-3.49
Minority Interests
0.00
-100.00%
0.08
-54.22%
0.17
-39.19%
0.27
Normalized Income
-11.81
+27.31%
-16.25
-253.85%
-4.59
-69.21%
-2.71
Net Income Common Stockholders
-11.91
+27.56%
-16.44
-232.72%
-4.94
-53.72%
-3.21
Diluted EPS
—
-394.94
-382.54%
-81.85
-53.72%
-53.24
Basic EPS
—
-394.94
-382.54%
-81.85
-53.72%
-53.24
Basic Average Shares
—
0.04
-31.05%
0.06
+0.00%
0.06
Diluted Average Shares
—
0.04
-31.05%
0.06
+0.00%
0.06
Diluted NI Availto Com Stockholders
-11.91
+27.56%
-16.44
-232.72%
-4.94
-53.72%
-3.21
Depreciation Amortization Depletion Income Statement
0.01
-44.00%
0.03
-44.44%
0.04
-21.05%
0.06
Depreciation And Amortization In Income Statement
0.01
-44.00%
0.03
-44.44%
0.04
-21.05%
0.06
Depreciation Income Statement
0.01
-44.00%
0.03
-44.44%
0.04
-21.05%
0.06
Rent And Landing Fees
0.18
+98.88%
0.09
+3.49%
0.09
+21.13%
0.07
Rent Expense Supplemental
0.18
+98.88%
0.09
+3.49%
0.09
+21.13%
0.07
Total Other Finance Cost
—
4.83
+161066.67%
0.00
-96.47%
0.09
Line Item Trend 2024-12-31
Total Assets
2.86
Current Assets
2.25
Cash Cash Equivalents And Short Term Investments
1.19
Cash And Cash Equivalents
1.19
Prepaid Assets
0.97
Restricted Cash
0.04
Other Current Assets
0.06
Total Non Current Assets
0.61
Net PPE
0.56
Gross PPE
0.63
Accumulated Depreciation
-0.07
Properties
0.00
Machinery Furniture Equipment
0.10
Other Properties
0.53
Leases
0.00
Non Current Prepaid Assets
0.01
Other Non Current Assets
0.05
Total Liabilities Net Minority Interest
6.85
Current Liabilities
3.52
Payables And Accrued Expenses
1.72
Payables
0.98
Accounts Payable
0.93
Current Accrued Expenses
0.74
Pensionand Other Post Retirement Benefit Plans Current
0.64
Total Tax Payable
0.05
Income Tax Payable
0.05
Current Debt And Capital Lease Obligation
1.16
Current Debt
1.00
Other Current Borrowings
1.00
Current Capital Lease Obligation
0.16
Other Current Liabilities
0.00
Total Non Current Liabilities Net Minority Interest
3.33
Long Term Debt And Capital Lease Obligation
3.33
Long Term Debt
2.96
Long Term Capital Lease Obligation
0.37
Preferred Securities Outside Stock Equity
0.00
Stockholders Equity
-3.99
Common Stock Equity
-3.99
Capital Stock
0.00
Common Stock
0.00
Share Issued
0.12
Ordinary Shares Number
0.12
Treasury Shares Number
0.00
Additional Paid In Capital
39.26
Retained Earnings
-43.25
Minority Interest
0.00
Total Equity Gross Minority Interest
-3.99
Total Capitalization
-1.03
Working Capital
-1.27
Invested Capital
-0.02
Total Debt
4.49
Net Debt
2.78
Capital Lease Obligations
0.53
Net Tangible Assets
-3.99
Tangible Book Value
-3.99
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-10.82
-28.86%
-8.40
-85.38%
-4.53
-35.80%
-3.33
Cash Flow From Continuing Operating Activities
-10.82
-28.86%
-8.40
-85.38%
-4.53
-35.80%
-3.33
Net Income From Continuing Operations
-11.91
+27.89%
-16.52
-223.39%
-5.11
-46.44%
-3.49
Depreciation Amortization Depletion
0.01
-44.00%
0.03
-44.44%
0.04
-21.05%
0.06
Depreciation
0.01
-44.00%
0.03
-44.44%
0.04
-21.05%
0.06
Depreciation And Amortization
0.01
-44.00%
0.03
-44.44%
0.04
-21.05%
0.06
Other Non Cash Items
0.34
-90.95%
3.80
+1094.97%
0.32
+218.66%
-0.27
Stock Based Compensation
0.13
-97.71%
5.86
+4409.23%
0.13
+4.00%
0.12
Operating Gains Losses
—
0.02
+1700.00%
-0.00
—
Gain Loss On Sale Of PPE
0.00
-100.00%
0.02
+1700.00%
-0.00
0.00
Change In Working Capital
0.60
+138.04%
-1.58
-1916.09%
0.09
-63.60%
0.24
Change In Receivables
—
—
0.02
+145.00%
-0.04
Change In Prepaid Assets
0.40
+162.76%
-0.63
-91.79%
-0.33
-179.28%
0.41
Change In Payables And Accrued Expense
-0.04
+96.90%
-1.29
-394.29%
0.44
+993.88%
-0.05
Change In Accrued Expense
0.10
+105.37%
-1.90
-628.97%
0.36
+3363.64%
-0.01
Change In Payable
-0.14
-123.28%
0.61
+672.15%
0.08
+307.89%
-0.04
Change In Account Payable
-0.14
-123.28%
0.61
+672.15%
0.08
+307.89%
-0.04
Change In Other Working Capital
0.23
-38.62%
0.38
+1045.00%
-0.04
+54.02%
-0.09
Change In Other Current Assets
0.01
+134.21%
-0.04
-311.11%
0.02
—
Investing Cash Flow
-0.01
+36.36%
-0.02
-103.84%
0.57
+209.35%
-0.52
Cash Flow From Continuing Investing Activities
-0.01
+36.36%
-0.02
-103.84%
0.57
+209.35%
-0.52
Net PPE Purchase And Sale
-0.01
+59.09%
-0.02
-133.33%
0.07
+265.00%
-0.04
Purchase Of PPE
-0.01
+59.09%
-0.02
-83.33%
-0.01
+70.00%
-0.04
Sale Of PPE
—
0.00
-100.00%
0.08
0.00
Capital Expenditure
-0.01
+59.09%
-0.02
-83.33%
-0.01
+70.00%
-0.04
Net Investment Purchase And Sale
-0.01
0.00
-100.00%
0.51
+204.75%
-0.48
Purchase Of Investment
-0.01
0.00
0.00
+100.00%
-0.50
Sale Of Investment
—
0.00
-100.00%
0.51
+3068.75%
0.02
Financing Cash Flow
15.64
+206.43%
5.10
+877.78%
0.52
-81.03%
2.75
Cash Flow From Continuing Financing Activities
15.64
+206.43%
5.10
+877.78%
0.52
-81.03%
2.75
Net Issuance Payments Of Debt
-0.70
-178.40%
-0.25
0.00
—
Repayment Of Debt
-0.70
-178.40%
-0.25
0.00
—
Long Term Debt Payments
-0.70
-178.40%
-0.25
0.00
—
Net Long Term Debt Issuance
-0.70
-178.40%
-0.25
0.00
—
Net Common Stock Issuance
16.04
+425.08%
3.05
0.00
—
Proceeds From Stock Option Exercised
—
—
0.00
-100.00%
0.00
Net Other Financing Charges
-2.34
-201.91%
2.30
—
—
Changes In Cash
4.81
+245.05%
-3.31
+3.49%
-3.43
-210.21%
-1.11
Effect Of Exchange Rate Changes
-0.00
+96.72%
-0.06
+73.48%
-0.23
+65.52%
-0.67
Beginning Cash Position
1.27
-72.66%
4.64
-44.10%
8.31
-17.59%
10.08
End Cash Position
6.08
+378.35%
1.27
-72.66%
4.64
-44.10%
8.31
Free Cash Flow
-10.83
-28.63%
-8.42
-85.38%
-4.54
-34.55%
-3.38
Interest Paid Supplemental Data
0.01
-51.85%
0.03
—
—
Common Stock Issuance
16.04
+425.08%
3.05
0.00
—
Issuance Of Capital Stock
18.68
+511.66%
3.05
+485.06%
0.52
-81.01%
2.75
Net Preferred Stock Issuance
2.64
0.00
-100.00%
0.52
-81.01%
2.75
Preferred Stock Issuance
2.64
0.00
-100.00%
0.52
-81.01%
2.75
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category